News

The 15-year clinical study demonstrated that more than 80% of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of

NextBio Enterprise offers life sciences organisations tools for knowledge discovery and collaboration, seamless integration of internal and external research data, and secure data access. Saeid Akhtari, co-founder and

The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex’s development plan regarding the proposed preclinical

Genta has recently completed a dose-ranging and pharmacokinetic study using Tesetaxel administered once every 3 weeks, a schedule that has shown anticancer activity in several Phase 2 clinical

Reportedly, Kyowa Hakko Kirin has confirmed KW-2246’s safety and efficacy in clinical trials conducted in Japan. The drug will be marketed by Kyowa Hakko Kirin and Hisamitsu Pharmaceutical.

According to the warning letter, Eli Lilly was unsuccessful in carrying out sufficient investigation of critical deviations and the failure of a batch to satisfy its quality standards

miR-122 is a liver-expressed microRNA that has been shown to be a critical endogenous ‘host factor’ for the replication of HCV and anti-miRs targeting miR-122 have been shown

LSO’s global Phase 3 trial of Aptocine in metastatic colorectal cancer (MCRC) has reached target enrollment of 450 patients at 52 sites. The controlled, randomised MCRC trial is

The drug discovery expertise includes fragment screening, structural biology and protein crystallography, to discover and profile novel compounds against additional antibacterial targets selected by Cubist. Evotec and Cubist